Provenge Nod Lifts Spirits And Stocks, But Also Sets High Bar For Success

Approval of Dendreon's Provenge is a major achievement and a shot in the arm for the growing field of therapeutic cancer vaccines, but it also serves as a reminder of the high bar for clinical and regulatory success in uncharted territory